Condition: Cancer · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC (Non-small Cell Lung Cancer) · Sponsor: Alterome Therapeutics, Inc.
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
This description comes directly from the study's public registry record.
Alterome Clinical Trial Contact Center · 619-768-8189 · clinical.trials@alterome.com
Always discuss trial participation with your own doctor first.
| Research Site | Orlando, Florida, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | St Louis, Missouri, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Durham, North Carolina, United States | Recruiting |
| Research Site | Nashville, Tennessee, United States | Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site #2 | San Antonio, Texas, United States | Recruiting |
| Research Site | San Antonio, Texas, United States | Recruiting |
| Research Site | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06835569